Atea Pharmaceuticals (AVIR) Set to Post Earnings on Wednesday

Key Points

• Atea Pharmaceuticals is expected to report Q3 2026 results after the market closes November 11, with analysts forecasting a loss of $0.51 per share and revenue of $50.45 million.
• In its previous quarter, Atea reported a loss of $0.41 per share, beating the consensus estimate of a $0.56 loss. Analysts expect full-year EPS of negative $1.99.
• The stock has a consensus Hold rating and an average price target of $7.00; shares recently opened at $4.33.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.51) per share and revenue of $50.45 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.15. On average, analysts expect Atea Pharmaceuticals to post ($1.99) EPS for the current fiscal year and ($1.48) EPS for the next fiscal year.

Atea Pharmaceuticals Stock Up 3.8%

Shares of AVIR stock opened at $4.33 on Wednesday. Atea Pharmaceuticals has a 12-month low of $2.87 and a 12-month high of $6.45. The firm has a fifty day moving average of $4.99 and a 200-day moving average of $4.91. The firm has a market capitalization of $347.31 million, a price-to-earnings ratio of -2.04 and a beta of 0.76.

Analysts Set New Price Targets

AVIR has been the topic of several analyst reports. Morgan Stanley upped their price target on shares of Atea Pharmaceuticals from $6.00 to $7.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 13th. Wall Street Zen upgraded shares of Atea Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, September 12th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Atea Pharmaceuticals in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $7.00.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral therapies for serious infectious diseases. The company's research platform is based on nucleotide and nucleoside prodrug technologies designed to target viral replication.

Atea's lead product candidate is bemnifosbuvir, formerly known as AT-527, an orally administered antiviral that has been evaluated for the treatment of COVID-19. The company has also investigated bemnifosbuvir and related antiviral approaches for other viral infections, including hepatitis C.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.